Oak Ridge Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

Oak Ridge Investments’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-121,504	Closed	-$3.34M	–	176
2019 Q3	$3.34M	Sell	121,504 -11,103	-8%	-$329K	0.25%	102
2019 Q2	$4.39M	Sell	132,607 -16,367	-11%	-$561K	0.3%	100
2019 Q1	$5.22M	Buy	148,974 +2,235	+2%	+$83.2K	0.33%	99
2018 Q4	$4.88M	Sell	146,739 -17,217	-11%	-$740K	0.35%	99
2018 Q3	$8.26M	Sell	163,956 -17,327	-10%	-$856K	0.46%	85
2018 Q2	$10.8M	Sell	181,283 -18,759	-9%	-$972K	0.61%	66
2018 Q1	$9.16M	Sell	200,042 -60,634	-23%	-$2.53M	0.51%	80
2017 Q4	$10.4M	Buy	260,676 +86,104	+49%	+$3.4M	0.5%	76
2017 Q3	$6.98M	Buy	+174,572	New	+$7.55M	0.28%	99

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oak Ridge Investments's SUPN Position: Q4 2019 in Review

Oak Ridge Investments sold out of Supernus Pharmaceuticals (SUPN) in Q4 2019, closing a stake of 121,504 shares — an estimated $3.34M sold.

Oak Ridge Investments first reported a position in SUPN in Q3 2017 and held it in 9 quarters. The position peaked at $10.8M in Q2 2018. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2019.

Oak Ridge Investments reported no remaining Supernus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Oak Ridge Investments sold 121,504 Supernus Pharmaceuticals shares in Q4 2019, an estimated $3.34M.
Oak Ridge Investments first reported a position in Supernus Pharmaceuticals in Q3 2017 and held it in 9 quarters.
Oak Ridge Investments's Supernus Pharmaceuticals position peaked at $10.8M in Q2 2018.
235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2019.

Based on Oak Ridge Investments's 13F filing for Q4 2019, filed 5 Feb 2020.